XML 46 R35.htm IDEA: XBRL DOCUMENT
v3.25.3

General (Details) $ in Thousands | 1 Months Ended |  |  |  |
--- | --- | --- | --- | --- | ---
Jun. 30, 2025 | Oct. 18, 2025 patient | Sep. 30, 2025 USD ($) site designation patient | Apr. 28, 2025 site patient | Dec. 31, 2024 USD ($)
Organization Consolidation Basis Of Presentation Business Description And Accounting Policies [Line Items] |  |  |  |  |
Cash cash equivalents and restricted cash | $ |  |  | $ 41,800 |  |
Short-term investments | $ |  |  | $ 47,099 |  | $ 20,821
HEPZATO KIT |  |  |  |  |
Organization Consolidation Basis Of Presentation Business Description And Accounting Policies [Line Items] |  |  |  |  |
Number of orphan drug designations granted by FDA |  |  | 6 |  |
Clinical trial, number of patients | patient |  |  | 90 | 90 |
Clinical trial, number of sites | site |  |  | 20 | 20 |
HEPZATO KIT, Melphalan |  |  |  |  |
Organization Consolidation Basis Of Presentation Business Description And Accounting Policies [Line Items] |  |  |  |  |
Number of orphan drug designations granted by FDA |  |  | 5 |  |
HEPZATO KIT, Doxorubicin |  |  |  |  |
Organization Consolidation Basis Of Presentation Business Description And Accounting Policies [Line Items] |  |  |  |  |
Number of orphan drug designations granted by FDA |  |  | 1 |  |
CHEMOSAT |  |  |  |  |
Organization Consolidation Basis Of Presentation Business Description And Accounting Policies [Line Items] |  |  |  |  |
Product reimbursement period | 2 years |  |  |  |
CHEMOSAT | Subsequent Event |  |  |  |  |
Organization Consolidation Basis Of Presentation Business Description And Accounting Policies [Line Items] |  |  |  |  |
Clinical trial, number of patients | patient |  | 76 |  |  |

X
- Definition Clinical Trial, Number Of Patients + References No definition available. + Details
Name: | dcth_ClinicalTrialNumberOfPatients
Namespace Prefix: | dcth_
Data Type: | xbrli:integerItemType
Balance Type: | na
Period Type: | instant

X
- Definition Clinical Trial, Number Of Sites + References No definition available. + Details
Name: | dcth_ClinicalTrialNumberOfSites
Namespace Prefix: | dcth_
Data Type: | xbrli:integerItemType
Balance Type: | na
Period Type: | instant

X
- Definition Number of Orphan Drug Designations Granted by US Food and Drug Administration + References No definition available. + Details
Name: | dcth_NumberOfOrphanDrugDesignationsGrantedByUSFoodAndDrugAdministration
Namespace Prefix: | dcth_
Data Type: | xbrli:integerItemType
Balance Type: | na
Period Type: | instant

X
- Definition Organization consolidation basis of presentation business description and accounting policies line item. + References No definition available. + Details
Name: | dcth_OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesLineItems
Namespace Prefix: | dcth_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition Product Reimbursement Period + References No definition available. + Details
Name: | dcth_ProductReimbursementPeriod
Namespace Prefix: | dcth_
Data Type: | xbrli:durationItemType
Balance Type: | na
Period Type: | duration

X
- Definition Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), classified as current. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 320 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481830/320-10-45-2 Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 326 -SubTopic 30 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479130/326-30-45-1 + Details
Name: | us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | instant

X
- Definition Amount of cash and cash equivalent, and cash and cash equivalent restricted to withdrawal or usage; attributable to continuing operation. Cash includes, but is not limited to, currency on hand, demand deposit with financial institution, and account with general characteristic of demand deposit. Cash equivalent includes, but is not limited to, short-term, highly liquid investment that is both readily convertible to known amount of cash and so near maturity that it presents insignificant risk of change in value because of change in interest rate. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482913/230-10-50-8 Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 24 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24 Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-4 + Details
Name: | us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | instant

X
- Details
Name: | srt_ProductOrServiceAxis=dcth_HEPZATOKITMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=dcth_HEPZATOKITMelphalanMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=dcth_HEPZATOKITDoxorubicinMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=dcth_CHEMOSATMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |